Latest From Mesoblast Ltd.
Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.
US FDA agrees to plan to seek approval for ‘off the shelf’ cell therapy with Phase II data showing fewer major mucosal bleeding events in end-stage heart failure patients implanted with mechanical assist devices; confirmatory Phase III is set to begin this year.
Australian venture with Phase II-ready cell therapy in sights of Sumitomo Dainippon as Japanese firm looks to build regenerative medicine interests and pipeline ahead of major expiry.
Keeping Track: A Busy Week For Regenerative Medicine, A Surprise Priority Review For Vascepa, And Tazemetostat Aims For Accelerated Approval
The latest drug development news and highlights from our US FDA Performance Tracker.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Parent & Subsidiaries
- Mesoblast Ltd.
- Senior Management
Silviu Itescu, CEO & Managing Dir.
Josh Muntner, CFO
Fred Grossman, MD, CMO
- Contact Info
Phone: (61) 3 9639 6036
55 Collins St.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.